Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) Starts Presentation at NobleCon13
Eyegate Pharmaceuticals (NASDAQ: EYEG) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EGP-437, the company’s first product in clinical trials, incorporates a reformulated topically active corticosteroid that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. In addition, the company is developing, through its wholly owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties.…